{"product_id":"biolegend-142506","title":"Biolegend, 142506, APC anti-mouse CD138 (Syndecan-1) Antibody, 100μg","description":"\u003cp\u003eCD138, a member of the syndecan protein family, is a type I integral membrane heparin sulfate proteoglycan also known as Syndecan-1. Syndecan-1 participates in cell proliferation, cell migration, and cell matrix adhesion via interaction with collagen, fibronectin, and other soluble molecules (such as FGF-basic). It is expressed on normal and malignant plasma cells, pre-B cells, mesenchymal cells, epithelial cells, and endothelial cells.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Mouse mammary gland epithelial cell line NMuMG\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Red Laser (633 nm)\u003cbr\u003e\nApplication Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of frozen tissue3 and formalin-fixed paraffin embedded tissue4 and immunofluorescent staining2,3.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Jalkanen M, et al. 1985. J. Cell. Biol. 101:976. (FC) Miettinen H, et al. 1994. J. Cell. Sci. 107:1571. (IF) Li Q, et al. 2002. Cell 111:635. (IF, IHC) McCarthy BA, et al. 2012. BMC Cancer. 12:203. (IHC)\u003cbr\u003e\nProduct Citations: Agrafiotis A, et al. 2023. iScience. 26:106055. PubMed Wang YC, et al. 2023. J Exp Med. 220:. PubMed Mi Z, et al. 2021. Vaccines (Basel). 10: . PubMed Su C, et al. 2022. NPJ Vaccines. 7:168. PubMed Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed Xiong E, et al. 2023. Front Immunol. 13:1083119. PubMed Zhu X, et al. 2017. Arch Oral Biol. 10.1016\/j.archoralbio.2017.03.010. PubMed Yao W, et al. 2019. Nature. 568:410. PubMed Delgado-Benito V, et al. 2020. J Exp Med. 217:00:00. PubMed Parthasarathy R, et al. 2021. Front Immunol. 12:758407. PubMed Wong R, et al. 2020. Immunity. 53(5):1078-1094.e7. PubMed Xiong Y, et al. 2018. Int J Clin Exp Pathol. 3.803472222. PubMed Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed Utley A, et al. 2020. Cell Rep. 31:107815. PubMed Ray A, et al. 2015. PLoS One. 10: 0137314. PubMed Qi T, et al. 2020. Cell Rep. 33:108452. PubMed Chen F et al. 2018. Cell reports. 25(10):2775-2783 . PubMed Li Z, et al. 2021. Cell Metabolism. 33(1):78-93.e7. PubMed Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed Roy K, et al. 2019. Immunity. 50:616. PubMed Chiu Y, et al. 2014. J Immunol. 193:2207. PubMed Minamitani T, et al. 2015. Proc Natl Acad Sci U S A. 112: 11612-11617. PubMed Rozanski C, et al. 2015. J Immunol. 194:4717. PubMed Castiblanco D, et al. 2017. Front Immunol. . 10.3389\/fimmu.2017.01833. PubMed Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed Xiao S, et al. 2020. Cell Reports. 32(2):107892. PubMed Chen C, et al. 2021. J Virol. 95:e0082921. PubMed Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed Han S, et al. 2016. Arthritis Res Ther. 0.975. PubMed Kiyohara H, et al. 2018. Cell Mol Gastroenterol Hepatol. 7:135. PubMed Cillo AR, et al. 2021. Cell Rep Med. 2:100476. PubMed Price MJ, et al. 2019. J Immunol. 203:2121. PubMed Vijay R, et al. 2021. J Exp Med. 218:. PubMed Wright JA, et al. 2021. Front Immunol. 12:705307. PubMed Xiong Y, et al. 2019. BMC Immunol. 20:24. PubMed Velazquez VM, et al. 2017. Mol Ther Methods Clin Dev. 0.277083333. PubMed Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed Zhang Y, et al. 2022. Front Pharmacol. 13:952775. PubMed Lightman SM, et al. 2020. Cell Reports. 1.086805556. PubMed Zhang M, et al. 2022. iScience. 25:104490. PubMed Alrefai H, et al. 2016. Nat Commun. 7:11724. PubMed Whiteley AM et al. 2017. eLife. 6 pii: e26435. PubMed\u003cbr\u003e\nRRID: AB_10960141 (BioLegend Cat. No. 142505) AB_10962911 (BioLegend Cat. No. 142506)\u003cbr\u003e\nStructure: Transmembrane heparan sulfate proteoglycan; member of the syndecan proteoglycan family, 100-200 kD\u003cbr\u003e\nFunction: Cell adhesion, cell motility, cell migration, cell proliferation\u003cbr\u003e\nCell Type: B cells\u003cbr\u003e\nBiology Area: Apoptosis\/Tumor Suppressors\/Cell Death, Cell Adhesion, Cell Biology, Cell Motility\/Cytoskeleton\/Structure, Immunology\u003cbr\u003e\nMolecular Family: Adhesion Molecules, CD Molecules\u003cbr\u003e\nAntigen References: 1. Zong F, et al. 2011. PLoS ONE 6:e14816. 2. Yamashita Y, et al. 1999. J. Immunol. 162:5940. 3. Sanderson RD, et al. 1989. Cell. Regul. 1:27.\u003cbr\u003e\nGene ID: 20969\u003cbr\u003e\nUniProt: View information about CD138 on UniProt.org\u003cbr\u003e\nClone: 281-2\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: Syndecan-1\u003cbr\u003e\nIsotype: Rat IgG2a, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46860883656873,"sku":"142506","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-142506","provider":"Iright","version":"1.0","type":"link"}